China
Africa
Explore chapters and articles related to this topic
Immunotherapy of Graves’ Eye Disease
Published in George S. Eisenbarth, Immunotherapy of Diabetes and Selected Autoimmune Diseases, 2019
N. R. Farid, G. Kahaly, J. Beyer
Garber26 treated 15 patients with 10 to 15 mg methylprednisolone acetate between 2 and 18 times, over a period of 2 to 24 months. There were moderate to dramatic improvements. Riley55 initially treated 27 patients with Graves’ ophthalmopathy of moderate severity with methylprednisolone acetate every 2 weeks, and later with Celestone Soluspan® every 3 to 4 days. Finally, he administered a mixture of the 2 substances every 7 to 10 days. He reported slight improvement and warned against a long duration of treatment because of side effects.
Epidural (interlaminar, intraforaminal, and caudal) steroid injections for back pain and sciatica
Published in Harald Breivik, William I Campbell, Michael K Nicholas, Clinical Pain Management, 2008
Ivan N Ramos-Galvez, Ian D Goodall
Inadvertent intravascular injection of particulate steroids has been reported to cause cerebrovascular accidents, retinal infarcts, and deafness81 from the formation of microembolae. Methylprednisolone acetate forms aggregates when dissolved in local anesthetics more than other depot steroids.11
Percutaneous Treatment of Vertebral Bone Cyst
Published in Alexander R. Vaccaro, Christopher M. Bono, Minimally Invasive Spine Surgery, 2007
Kathleen S. Beebe, Joseph Benevenia
It is generally recommended that sclerotherapy be performed utilizing general anesthesia in the operating room or in the angiography suite. The technique for injection involves direct puncture of the cyst under CT or fluoroscopic guidance using a 14- to 18-gauge needle. Blood return should be noted and fluid may then be aspirated. Contrast medium is then injected into the lesion to demonstrate filling of the cyst. The volume of contrast material should be noted. If complete filling of the cyst does not occur, additional injection sites may be required. Incomplete filling may be the result of septations within the lesion. The venous drainage of the contrast material should also be assessed. It should be minimal. Without the ability to compress the venous drainage system, areas with marked venous drainage should not be injected, as this can risk embolization of the venous system (10). In areas around vital structures, histoacryl may be the sclerosing agent of choice. An amount equal to the injected contrast material needed to fully opacify the cyst should be utilized. This should be injected slowly with minimal pressure (11). Alternatively, injection with methylprednisolone acetate (80 to 125 mg) in conjunction with calcitonin (100 to 200 IU) may also be used (7,8).
Reduction of systemic exposure and side effects by intra-articular injection of anti-inflammatory agents for osteoarthritis: what is the safer strategy?
Published in Journal of Drug Targeting, 2023
Zuoxu Xie, Lu Wang, Jie Chen, Zicong Zheng, Songpol Srinual, Annie Guo, Rongjin Sun, Ming Hu
Clinical studies on IA corticosteroids for OA have been conducted as early as the 1950s [24]. Since then, many of the corticosteroids through IA injection have been approved by the regulatory authorities. Currently, FDA has approved methylprednisolone acetate, triamcinolone acetate (TCA), betamethasone acetate, betamethasone sodium phosphate, triamcinolone hexacetonide, and dexamethasone, for treating OA by IA injection. Generally, IA corticosteroids are recommended for short-term relief to the pain and swelling in the joint (Table 1). Meanwhile, repeated IA corticosteroids have brought up safety concerns, which will be further discussed in the later part of this review.
Improvement of bone microarchitecture in methylprednisolone induced rat model of osteoporosis by using thiolated chitosan-based risedronate mucoadhesive film
Published in Drug Development and Industrial Pharmacy, 2018
Dhrubojyoti Mukherjee, Bharath Srinivasan, J. Anbu, Mohammad Azamthulla, Venkatesh Teja Banala, S. G. Ramachandra
Risedronate sodium was a gift sample from Fleming Laboratories, Hyderabad, India. Chitosan was procured from Indian Institute of Fisheries, Cochin, India. HPMC-4 KM, ethylcellulose and thioglycolic acid (TGA) were obtained commercially from SD Fine Chemicals, Mumbai, India. Dialysis membrane-70 was procured from Hi Media Laboratories Pvt. Ltd., Mumbai, India. Ketamine HCl and Lidocaine HCl were obtained from Neon Laboratories Limited, Mumbai, India. Methylprednisolone acetate was obtained from Pfizer Products Pvt. Ltd, Mumbai, India. All other reagents and chemicals used were of analytical reagent grade.
Improved treatment efficacy of risedronate functionalized chitosan nanoparticles in osteoporosis: formulation development, in vivo, and molecular modelling studies
Published in Journal of Microencapsulation, 2019
Shivalingappa Santhosh, Dhrubojyoti Mukherjee, Jayaraman Anbu, Manikanta Murahari, Banala Venkatesh Teja
Risedronate sodium was gifted by Fleming Laboratories, Hyderabad, India. Medium molecular weight chitosan (Mw = 190–310 KDa, 85% deacetylated) was purchased from Indian Institute of Fisheries, Cochin, India. Sodium hydroxide was purchased from Vetec, Bangalore, India. Sodium orthophosphate was obtained commercially from Himedia Laboratories Pvt. Ltd., Mumbai, India. Methylprednisolone acetate was purchased from Pfizer products Pvt. Ltd, Mumbai, India. Lidocaine HCl and Ketamine HCl were purchased from Neon laboratories limited, Andheri, Mumbai, India. All other reagents were of analytical reagent grade.